Life after Lyxumia: Ex-Zealand CEO Solomon's next quest is to cure HIV

David Horn Solomon spent six years heading up Zealand Pharma, developer of the GLP-1 agonist Lyxumia (lixisenatide), which has travelled a bumpy road in the hands of licensing partner Sanofi. He is now CEO of Bionor Pharma, a company that is hoping to make headway with its HIV vaccine. Rather a challenge, but Dr Solomon believes the company is a clear two years ahead of the competition and with his guidance stands a real chance of being the first to tackle the 'What's next?' question in the treatment of HIV.